Maxcyte (MXCT) Depreciation & Amortization (CF) (2020 - 2026)

Maxcyte (MXCT) has 7 years of Depreciation & Amortization (CF) data on file, last reported at $1.0 million in Q1 2026.

• Quarterly Depreciation & Amortization (CF) fell 4.47% year-over-year to $1.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.3 million (changed 0.21% YoY) and the FY2025 annual result came in at $4.3 million, up 0.58% from the prior year.
• Depreciation & Amortization (CF) declined to $1.0 million in Q1 2026 per MXCT's latest filing, from $1.1 million in the prior quarter.
• Across five years, Depreciation & Amortization (CF) topped out at $1.1 million in Q1 2024 and bottomed at $487400.0 in Q1 2022.
• The 5-year median for Depreciation & Amortization (CF) is $1.1 million (2024), against an average of $974752.9.
• The widest annual swing landed in 2022, when Depreciation & Amortization (CF) jumped 120.82%; it then fell 4.47% in 2026.
• Tracing MXCT's Depreciation & Amortization (CF) over 5 years: stood at $919700.0 in 2022, then grew by 19.82% to $1.1 million in 2023, then fell by 4.08% to $1.1 million in 2024, then advanced by 1.42% to $1.1 million in 2025, then declined by 2.33% to $1.0 million in 2026.
• Per Business Quant, the three latest MXCT Depreciation & Amortization (CF) figures stand at $1.0 million (Q1 2026), $1.1 million (Q4 2025), and $1.1 million (Q3 2025).

Peer Comparison